Emend

DRUG2 trials

Sponsors

Heidelberg University, Merck Sharp & Dohme LLC

Conditions

Chemotherapy-induced Nausea and VomitingMultiple Myeloma

Phase 3

Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy

Heidelberg UniversityMultiple Myeloma

Start: 2005-07-31End: 2010-12-31Target: 362Updated: 2010-01-12

Unknown Phase

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

CompletedNCT01074255

Merck Sharp & Dohme LLCChemotherapy-induced Nausea and Vomiting

Start: 2007-04-30End: 2011-10-31Updated: 2015-04-21